No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PCRX240621C45000
- 0.76
- 0.000.00%
15min DelayTrading Dec 22 13:04 ET
0.00High0.00Low
0.00Open0.76Pre Close0 Volume30 Open Interest45.00Strike Price0.00Turnover406.34%IV66.22%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.76Extrinsic Value100Contract SizeAmericanOptions Type0.1551Delta0.0215Gamma36.22Leverage Ratio-0.3509Theta0.0003Rho5.62Eff Leverage0.0065Vega
Intraday
- 5D
- Daily
News
Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $36
Jefferies analyst Glen Santangelo maintains $Pacira BioSciences(PCRX.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 51.1% a
Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)
Pacira BioSciences(PCRX.US) Officer Sells US$143.19K in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer SLONIN JONATHAN sold 5,012 shares of common stock on Jun 11, 2024 at an average price of $28.57 for a total value of $143.19K.Source: Announcement What is stateme
Pacira BioSciences(PCRX.US) Officer Sells US$114.02K in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer RIKER LAUREN sold 3,970 shares of common stock on Jun 12, 2024 at an average price of $28.72 for a total value of $114.02K.Source: Announcement What is statement
Pacira BioSciences(PCRX.US) Director Sells US$24,974.4 in Common Stock
$Pacira BioSciences(PCRX.US)$ Director HASTINGS PAUL J sold 880 shares of common stock on Jun 13, 2024 at an average price of $28.38 for a total value of $24,974.4.Source: Announcement What is stateme
Pacira BioSciences(PCRX.US) Officer Sells US$211.49K in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer WILLIAMS KRISTEN sold 7,452 shares of common stock on Jun 13, 2024 at an average price of $28.38 for a total value of $211.49K.Source: Announcement What is statem
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more